A Phase 1b/2 Study of JNJ-90014496 in Adult Participants with B-cell Non-Hodgkin Lymphoma

2023-506267-33-00 Protocol 90014496LYM1001 Human pharmacology (Phase I) - Other Authorised, recruiting

Start 29 May 2024 · Status Authorised, recruiting · 6 EU/EEA countries · 16 sites · Protocol 90014496LYM1001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Authorised, recruiting
Participants planned 334
Countries 6
Sites 16

Non-Hodgkin Lymphoid Malignancies

Key facts

Sponsor
Janssen - Cilag International
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
29 May 2024 → ongoing
Decision date (initial)
2024-04-30
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Non-Hodgkin Lymphoid Malignancies

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Janssen - Cilag International

Sponsor organisation
Janssen - Cilag International
Address
Turnhoutseweg 30
City
Beerse
Postcode
2340
Country
Belgium

Scientific contact point

Organisation
Janssen - Cilag International
Contact name
CTIS Point of Contact

Public contact point

Organisation
Janssen - Cilag International
Contact name
CTIS Point of Contact

Locations

6 EU/EEA countries · 16 investigational sites

By country

CountryMS statusPlanned subjectsSites
Denmark Ongoing, recruitment ended 36 2
France Ended 4 2
Germany Not authorised 6 3
Italy Authorised, recruitment pending 6 3
Netherlands Ongoing, recruitment ended 25 2
Spain Ongoing, recruitment ended 26 4
Rest of world
Korea, Republic of, Australia, United Kingdom, United States, Canada
231

Investigational sites

Denmark

2 sites · Ongoing, recruitment ended
Odense University Hospital
Haematological Research unit HFE-X OUH, J B Winsloews Vej 4, 5000, Odense C
Rigshospitalet
Department of Haematology and Phase 1 Unit, Blegdamsvej 9, 2100, Copenhagen Oe

France

2 sites · Ended
Institut Universitaire Du Cancer Toulouse-Oncopole
Hematology Department, 1 Avenue Irene Joliot Curie, 31100, Toulouse
Centre Hospitalier Universitaire De Nantes
Hematology Department, 1 Place Alexis Ricordeau, 44000, Nantes

Germany

3 sites · Not authorised
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
III. Med. Klinik und Poliklinik, Langenbeckstrasse 1, Oberstadt, Mainz
Universitaetsklinikum Wuerzburg AöR
Medizinische Klinik und Poliklinik II des Universitaetsklinikums Zentrum Innere Medizin (ZIM), Oberduerrbacher Strasse 6, Grombuehl, Wuerzburg
Universitaetsklinikum Essen AöR
Klinik für Hämatologie und Stammzelltransplantation, Hufelandstrasse 55, Holsterhausen, Essen

Italy

3 sites · Authorised, recruitment pending
Humanitas Mirasole S.p.A.
UOC ONCOEMATOLOGIA, Via Alessandro Manzoni 56, 20089, Rozzano
Azienda Ospedaliero-Universitaria Ss.Antonio E Biagio E C.Arrigo Alessandria
Struttura Complessa a Direzione Universitaria di Ematologia, Via Venezia 16, 15121, Alexandria
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
UOC Hematology, Via Pietro Albertoni 15, 40138, Bologna

Netherlands

2 sites · Ongoing, recruitment ended
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Department of Hematology, Dr. Molewaterplein 40, 3015 GD, Rotterdam
Universitair Medisch Centrum Utrecht
Department of Hematology, Heidelberglaan 100, 3584 CX, Utrecht

Spain

4 sites · Ongoing, recruitment ended
Hospital Universitari Vall D Hebron
Hematology, Edificio Materno-Infantil, Passeig De La Vall D'hebron 119-129, Barcelona
Hospital Universitario Fundacion Jimenez Diaz
Hematology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Clinic De Barcelona
Hematology, Calle Villarroel 170, 08036, Barcelona
Institut Catala D'oncologia
Hematology Department, Avinguda De La Gran Via De L'hospitalet 199-203, 08908, L'hospitalet De Llobregat

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Denmark 2024-05-29 2024-06-03 2026-04-28
Netherlands 2024-06-21 2024-07-05 2026-04-28
Spain 2024-07-10 2024-10-02 2026-04-28

Application history

11 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-01-16 Denmark Acceptable
2024-04-29
2024-04-30
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-05-17 Denmark Acceptable
2024-04-29
2024-05-17
3 SUBSTANTIAL MODIFICATION SM-1 2024-06-14 Acceptable 2024-08-06
4 SUBSTANTIAL MODIFICATION SM-2 2024-08-01 Acceptable 2024-08-08
5 SUBSTANTIAL MODIFICATION SM-3 2024-09-04 Acceptable 2024-09-19
6 SUBSTANTIAL MODIFICATION SM-4 2024-11-12 Acceptable 2024-12-05
7 SUBSTANTIAL MODIFICATION SM-5 2025-02-26 Denmark Acceptable
2025-05-26
2025-05-27
8 SUBSTANTIAL MODIFICATION SM-6 2025-07-23 Denmark Acceptable
2025-10-07
2025-10-07
9 SUBSEQUENT ADDITION OF MSC APP-9 2025-10-28 Acceptable
2025-10-07
2026-01-20
10 SUBSTANTIAL MODIFICATION SM-7 2025-10-29 Acceptable 2025-11-05
11 SUBSTANTIAL MODIFICATION SM-8 2026-02-10 Denmark Acceptable
2026-05-04
2026-05-05